- Home
- CDLR vs DNLI Comparison
CDLR vs DNLI Comparison
Compare CDLR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- DNLI
- Stock Information
- Founded
- CDLR 2008
- DNLI 2013
- Country
- CDLR Denmark
- DNLI United States
- Employees
- CDLR N/A
- DNLI N/A
- Industry
- CDLR
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDLR
- DNLI Health Care
- Exchange
- CDLR Nasdaq
- DNLI Nasdaq
- Market Cap
- CDLR 1.9B
- DNLI 2.1B
- IPO Year
- CDLR N/A
- DNLI 2017
- Fundamental
- Price
- CDLR $21.15
- DNLI $14.18
- Analyst Decision
- CDLR
- DNLI Strong Buy
- Analyst Count
- CDLR 0
- DNLI 15
- Target Price
- CDLR N/A
- DNLI $33.85
- AVG Volume (30 Days)
- CDLR 39.3K
- DNLI 1.5M
- Earning Date
- CDLR 08-26-2025
- DNLI 08-12-2025
- Dividend Yield
- CDLR N/A
- DNLI N/A
- EPS Growth
- CDLR N/A
- DNLI N/A
- EPS
- CDLR 0.31
- DNLI N/A
- Revenue
- CDLR $319,011,025.00
- DNLI N/A
- Revenue This Year
- CDLR $111.36
- DNLI N/A
- Revenue Next Year
- CDLR $83.35
- DNLI $323.34
- P/E Ratio
- CDLR $18.98
- DNLI N/A
- Revenue Growth
- CDLR 171.33
- DNLI N/A
- 52 Week Low
- CDLR $17.37
- DNLI $10.57
- 52 Week High
- CDLR $28.75
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CDLR 44.88
- DNLI 49.54
- Support Level
- CDLR $20.30
- DNLI $13.25
- Resistance Level
- CDLR $22.39
- DNLI $14.53
- Average True Range (ATR)
- CDLR 0.34
- DNLI 0.68
- MACD
- CDLR -0.12
- DNLI -0.00
- Stochastic Oscillator
- CDLR 18.14
- DNLI 43.68
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.